An overview of statin-induced myopathy and perspectives for the future.

An overview of statin-induced myopathy and perspectives for the future. Expert Opin Drug Saf. 2020 Apr 01;: Authors: Nikolic D, Banach M, Chianetta R, Luzzu LM, Pantea Stoian A, Diaconu CC, Citarrella R, Montalto G, Rizzo M Abstract Introduction: Statins remain the most commonly prescribed lipid-lowering drug class for the treatment of atherosclerotic cardiovascular disease. Their well-recognized side effects are known as statin-associated muscle symptom (SAMS). Some advances in this field have been made in recent years, but the understanding of the mechanisms has lagged. Investigating the specific role of the anti-HMGCR autoantibody, pharmacokinetic genetic variants, characterization of the known phenotypes of statin toxicity, in relation to clinical markers of disease, is of high importance.Areas covered: We summarized currently available findings (on PubMed) related to SAMS and discussed the therapeutic approaches, risk factors, drug interactions, potential novel systems, algorithms and biomarkers for SAMS detection. CoQ10 supplementation has been suggested as a complementary approach to manage SAMS, while vitamin D levels may be useful for both the diagnosis and management. Expert Opinion/Commentary: Further studies might help to understand the easiest way to diagnose SAMS, suitable prevention and an effective non-statin therapy. This review sheds new light on the future directions in both research and clinical practice, which will help with rapid ris...
Source: Expert Opinion on Drug Safety - Category: Drugs & Pharmacology Tags: Expert Opin Drug Saf Source Type: research

Related Links:

How prevalent is statin use among terminally ill nursing home residents? Should statins be discontinued in those unlikely to benefit from continued use?Journal of the American Geriatrics Society
Source: Medscape Today Headlines - Category: Consumer Health News Tags: Family Medicine/Primary Care Journal Article Source Type: news
CONCLUSIONS: ACS patients with DM showed weaker coronary plaque regression than their counterparts. A significant correlation between the change in LDL-C level and ΔPAV in DM patients suggested that more intensive lipid-lowering therapy is required in ACS patients with DM. PMID: 32435011 [PubMed - as supplied by publisher]
Source: Journal of Atherosclerosis and Thrombosis - Category: Cardiology Tags: J Atheroscler Thromb Source Type: research
There are clear gender differences in the medication prescribed in primary care to adults with or at high risk for heart disease, with women less apt than men to receive aspirin and statins, a new study indicates.Reuters Health Information
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Cardiology News Source Type: news
Conditions:   Hypercholesterolemia;   Chronic Kidney Disease Requiring Chronic Dialysis Interventions:   Drug: Evolocumab + ezetimibe;   Drug: Placebo + ezetimibe Sponsors:   Policlinico Casilino ASL RMB;   IRCCS San Raffaele Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
ConclusionAmong patients with CAD, BB exposure is associated with reduced risk of death. The association is strongest among those who have suffered MI. This favorable association appears durable beyond 3  years.
Source: European Journal of Clinical Pharmacology - Category: Drugs & Pharmacology Source Type: research
Conditions:   Hypercholesterolemia;   Chronic Kidney Disease Requiring Chronic Dialysis Interventions:   Drug: Evolocumab + ezetimibe;   Drug: Placebo + ezetimibe Sponsors:   Policlinico Casilino ASL RMB;   IRCCS San Raffaele Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Hepatitis D virus (HDV) infection may induce fulminant hepatitis in chronic hepatitis B patients (CHB) or rapid progression of CHB to cirrhosis or hepatocellular carcinoma. There is no effective treatment for ...
Source: Journal of Biomedical Science - Category: Biomedical Science Authors: Tags: Research Source Type: research
Pro-protein convertase subtilisin/kexin type 9 (PCSK-9) inhibitors are currently a class 1 recommendation for the secondary prevention of atherosclerotic cardiovascular disease (ASCVD) in patients judged to be at very high risk for future ASCVD events in addition to maximally tolerated statins and ezetimibe.1 Recently, Inclisiran, a chemically synthesized small interfering RNA therapeutic agent that reduces hepatic synthesis of PCSK9 was developed with the intent to reduce plasma low-density lipoprotein-cholesterol (LDL-C) levels.
Source: The American Journal of Cardiology - Category: Cardiology Authors: Source Type: research
Nature Reviews Cardiology, Published online: 21 May 2020; doi:10.1038/s41569-020-0396-6Individuals with obesity have an increased prevalence of the Bacteroides 2 enterotype, which is associated with systemic inflammation and disease. However, statin therapy is associated with a reduced prevalence of this dysbiosis in individuals with obesity.
Source: Nature Reviews Cardiology - Category: Cardiology Authors: Source Type: research
Statins are associated with muscle-related adverse events, but few studies have investigated the association with fall-related hospitalizations among residents of long-term care facilities (LTCFs).
Source: Journal of Clinical Lipidology - Category: Lipidology Authors: Tags: Original Research Source Type: research
More News: Cardiology | Cardiovascular | Cholesterol | Drugs & Pharmacology | Genetics | Heart | Statin Therapy | Study | Toxicology | Vitamin D | Vitamins